Company / Total Assets
Lineage Cell Therapeutics, Inc. Total Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$112.6M
FY2025
5-year range
$101.0M / $174.5M
FY2021-FY2025
Trend
-0.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Total Assets has fluctuated over the past 10 years, ranging from $101M in FY2023 to $175M in FY2021.
Based on SEC 10-K filings.
$113M in FY2025 with a 5-year CAGR of +0.8%.
Improved from $101M to $113M over the past 2 years.
Total Assets over time
Growth rates
- 3-Year CAGR
- -3.1%
- 5-Year CAGR
- +0.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +0.8%, indicating consistent growth.
- In FY2025, total assets decreased 0.6% year-over-year.
- Peak total assets was recorded in FY2021.
- Lowest total assets in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $112.6M | -0.6% |
| FY2024 | $113.2M | +12.1% |
| FY2023 | $101.0M | -18.3% |
| FY2022 | $123.7M | -29.2% |
| FY2021 | $174.5M | +61.7% |
| FY2020 | $107.9M | -14.0% |
| FY2019 | $125.5M | +23.4% |
| FY2018 | $101.7M | -41.3% |
| FY2017 | $173.2M | +21.5% |
| FY2016 | $142.6M | +50.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026